Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07300267 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
A Phase 1 study of Pneumococcal Infection, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 210
- Enrollment target
- 12
- Study locations
NCT07300267: Recruiting Phase 1 study of Pneumococcal Infection, sponsored by Merck Sharp & Dohme.
NCT07300267 is a Phase 1 study of Pneumococcal Infection that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 210 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (250% higher). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07300267, a Phase 1 study of Pneumococcal Infection, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 210 participants
- Enrollment target
- 12
- Study locations
Study Summary
Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae. V118C is a new vaccine designed to help prevent disease from Streptococcus pneumoniae bacteria. This study will look at V118C in toddlers and infants. The goal of the study is to learn how safe V118C is for children and how well they tolerate it.
Primary Outcome
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants with immediate AEs following vaccination will be reported.
Conditions Studied
Interventions
- BIOLOGICAL V118C (Stage 1)
- BIOLOGICAL V118C (Stage 2)
- BIOLOGICAL PCV20 (Stage 1)
- BIOLOGICAL PCV20 (Stage 2)
Study Locations (12)
Texas
- Epic Medical Research - Carrollton ( Site 1038) - Carrollton
- Epic Medical Research- Garland ( Site 1017) - Garland
- University of Texas Medical Branch ( Site 1020) - League City
South Carolina
- Tribe Clinical Research, LLC-Pediatrics ( Site 1008) - Greenville
- Tribe Clinical Research - Spartanburg ( Site 1001) - Spartanburg
California
- Madera Family Medical Group ( Site 1004) - Madera
Florida
- Acevedo Clinical Research Associates ( Site 1029) - Miami
Kansas
- Cotton O'Neil Research Center ( Site 1039) - Topeka
Kentucky
- University of Louisville, Norton Children's Research Institute ( Site 1005) - Louisville
Missouri
- Saint Louis University Center for Vaccine Development ( Site 1031) - St Louis
New York
- Child Health Care Associates ( Site 1035) - East Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2026-01-13 |
| Est. Completion | 2029-05-25 |
| Phase | Phase 1 |
What NCT07300267 shows while recruiting
NCT07300267 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (250% higher).
The record links to 1 condition, with Pneumococcal Infection appearing as the primary indexed condition, and to 4 interventions - of which V118C (Stage 1) is the first listed.
NCT07300267 lists 12 locations in 9 states (Texas, South Carolina, California).
Frequently Asked Questions
What is clinical trial NCT07300267 about?
NCT07300267 is a clinical study titled "A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)". Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae. V118C is a new vaccine designed to help prevent disease from Streptococcus pneumoniae bacteri...
What is the current status of trial NCT07300267?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 210 participants. The study started on 2026-01-13. Estimated completion is 2029-05-25.
What conditions does trial NCT07300267 study?
This clinical trial studies the following conditions: Pneumococcal Infection.
What interventions are being tested in trial NCT07300267?
The interventions under investigation include: V118C (Stage 1) (BIOLOGICAL), V118C (Stage 2) (BIOLOGICAL), PCV20 (Stage 1) (BIOLOGICAL), PCV20 (Stage 2) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07300267?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07300267 being conducted?
This trial has 12 study locations across California, Florida, Kansas, Kentucky, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumococcal Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07300267's enrollment target sits among peer trials
210 245th of 2000 higher than 1,751 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI